Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find one of our health articles more useful.
Treatment of almost all medical conditions has been affected by the COVID-19 pandemic. NICE has issued rapid update guidelines in relation to many of these. This guidance is changing frequently. Please visit https://www.nice.org.uk/covid-19 to see if there is temporary guidance issued by NICE in relation to the management of this condition, which may vary from the information given below.
A rare condition characterised by pronounced, diffuse, thickening of the ventricular endocardium. It appears as unexplained heart failure in infants and children.
The disease can be primary or secondary, although some argue it is only ever secondary.
The two forms of primary endocardial fibroelastosis (EFE) are dilated (most common), and contracted. It has been suggested that one form may progress to the other.
- Primary dilated EFE occurs when the heart is otherwise normal and there is no other cause of unexplained heart failure.
- Secondary dilated EFE is associated with aortic stenosis or atresia.
- Secondary contracted EFE is associated with hypoplastic left heart syndrome.
- It is rare - only 1-2% of all congenital heart diseases. The number of cases has fallen dramatically in recent years, possibly secondary to better antenatal scanning.
- It may be familial (10%) with a predominantly X-linked pattern.
- It affects both sexes equally, usually presenting during the first 3-6 months of life in 80% of cases.
- Typical age of diagnosis is 2-12 months. It rarely is reported in adolescents and adults.
- It is an important cause of non-immune hydrops fetalis.
Possible factors include:
- Intrauterine viral infection (mumps, Coxsackievirus B).
- Neonatal lupus syndrome.
- Subendocardial ischaemia.
- Impaired lymphatic drainage of the heart.
- Systemic carnitine deficiency.
It presents with typical signs of congestive heart failure (CHF) in previously healthy children less than 6 months old.
- Feeding difficulty
- Excessive sweating
- Failure to thrive
- Recurrent chest infections
In children, remember that severe abdominal pain may indicate coronary insufficiency.
- Respiratory distress during feeding - tachypnoea, grunting, subcostal or intercostal recession.
- Pallor (anaemia).
- Peripheral cyanosis.
- Cardiomegaly - normal or quiet first and second heart sounds, a gallop rhythm with an audible third heart sound.
- Apical pansystolic murmur.
- Blood tests:
- Blood urea and creatinine.
- Autoantibody profile (including anti-Ro and anti-La).
- Blood culture tests indicated for management of acute episodes.
- Cardiothoracic (CT) ratio exceeds 0.65.
- Left lower lobe atelectasis may be seen.
- The cardiac silhouette is often globular.
- Pulmonary venous congestion is common.
- Tall R waves.
- Deep Q waves.
- T-wave inversion or flattening in the left precordial or inferior lead.
- Findings depict left ventricular (LV) hypertrophy.
- Right axis deviation and isolated right ventricular (RV) hypertrophy (more common in the first few weeks of life).
- Left, right (or both) atrial enlargement.
- Wolff-Parkinson-White syndrome, left bundle branch block, supraventricular and ventricular arrhythmias and varying degrees of atrioventricular block.
- The early and terminal stages of heart failure show low-voltage tracings.
- Increase in left atrium and LV dimensions.
- Reduced ejection fraction.
- Abnormal mitral valve motion.
- Dense echogenicity along the endocardium of the LV.
- A varying degree of mitral regurgitation is common.
- Fetal echocardiography:
- Electron beam CT can demonstrate calcification and fibrosis of the ventricles (particularly at apex).
- Cardiac MRI.
This is the same as chronic cardiac failure:
- Acute exacerbations are often precipitated by respiratory infections.
- Early and prolonged treatment with digoxin is suggested. This may result in clinical improvement and reversion of the cardiac enlargement to normal. Therapy should be continued for several years after the symptoms disappear, as stopping the drug may result in acute cardiac failure.
- Steroid therapy (dexamethasone) has been shown to cure fetal endocardial fibroelastosis (EFE) and AV conduction delays associated with maternal anti-Ro and anti-La antibodies.
- Supportive measures for acute failure and exacerbations may be required, eg treatment of infection and anaemia.
- Thromboembolic complications may require anticoagulation.
Cardiac transplantation may be recommended for those with end-stage disease.
The prognosis for primary endocardial fibroelastosis (EFE) is relatively poor, although the condition is not universally fatal. There is a 4-year survival rate of 77%.
- Infants presenting with acute failure almost always die from the acute episode, unless they receive a transplant.
- Those with a chronic presentation have a 30-40% mortality rate from resistant heart failure.
- Acute congestive heart failure (CHF) becomes progressive CHF. Death occurs within weeks, usually in the first six months of life.
- One third of the patients survive and they can experience persistent symptoms, show residual ECG abnormalities or show evidence of cardiomegaly.
- Episodes of CHF recurring more than six months after initial onset of symptoms also indicate a poor prognosis.
Further reading and references
Hunter AS, Keay AJ; Primary endocardial fibroelastosis. An inherited condition. Arch Dis Child. 1973 Jan48(1):66-9.
Lurie PR; Changing concepts of endocardial fibroelastosis. Cardiol Young. 2010 Apr20(2):115-23. Epub 2010 Mar 29.
Carceller AM, Maroto E, Fouron JC; Dilated and contracted forms of primary endocardial fibroelastosis: a single fetal disease with two stages of development. Br Heart J. 1990 May63(5):311-3.
Rodriguez MM, Bruce JH, Jimenez XF, et al; Nonimmune hydrops fetalis in the liveborn: series of 32 autopsies. Pediatr Dev Pathol. 2005 May-Jun8(3):369-78. Epub 2005 Jul 14.
Ni J, Bowles NE, Kim YH, et al; Viral infection of the myocardium in endocardial fibroelastosis. Molecular evidence for the role of mumps virus as an etiologic agent. Circulation. 1997 Jan 795(1):133-9.
Tincani A, Rebaioli CB, Taglietti M, et al; Heart involvement in systemic lupus erythematosus, anti-phospholipid syndrome and Rheumatology (Oxford). 2006 Oct45 Suppl 4:iv8-13.
Venugopalan P; Endocardial Fibroelastosis, Medscape, Jun 2010
Valdes-Dapena M, Gilbert-Barness E; Cardiovascular causes for sudden infant death. Pediatr Pathol Mol Med. 2002 Mar-Apr21(2):195-211.
Steward CG, Newbury-Ecob RA, Hastings R, et al; Barth syndrome: an X-linked cause of fetal cardiomyopathy and stillbirth. Prenat Diagn. 2010 Oct30(10):970-6.
Buyon JP, Rupel A, Clancy RM; Neonatal lupus syndromes. Lupus. 200413(9):705-12.
Tannouri F, Rypens F, Peny MO, et al; Fetal endocardial fibroelastosis: ultrasonographic findings in two cases. J Ultrasound Med. 1998 Jan17(1):63-6.
Weiner Z, Shalev E; Doppler fetal echocardiography in endocardial fibroelastosis. Obstet Gynecol. 2001 Nov98(5 Pt 2):933-5.
Clur SA, van der Wal AC, Ottenkamp J, et al; Echocardiographic evaluation of fetal cardiac function: clinical and anatomical Fetal Diagn Ther. 201028(1):51-7. Epub 2010 Apr 16.
Wang IJ, Chen SJ, Wang JK, et al; Electron beam computed tomography appearance of endocardial fibroelastosis EBCT appearance of endocardial fibroelastosis. Int J Cardiovasc Imaging. 2003 Feb19(1):85-90.
Stranzinger E, Ensing GJ, Hernandez RJ; MR findings of endocardial fibroelastosis in children. Pediatr Radiol. 2008 Mar38(3):292-6. Epub 2008 Jan 3.
Mevorach D, Elchalal U, Rein AJ; Prevention of complete heart block in children of mothers with anti-SSA/Ro and Curr Opin Rheumatol. 2009 Sep21(5):478-82.
Ino T, Benson LN, Freedom RM, et al; Natural history and prognostic risk factors in endocardial fibroelastosis. Am J Cardiol. 1988 Sep 162(7):431-4.